E
AUTL

Ergoteles’s Autolus Therapeutics AUTL Stock Holding History

Ergoteles’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-169,180
Closed -$321K – 1248
2022
Q4 		$321K Buy
+169,180
New +$428K 0.01% 885

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Ergoteles's AUTL Position: Q1 2023 in Review

Ergoteles sold out of Autolus Therapeutics (AUTL) in Q1 2023, closing a stake of 169,180 shares — an estimated $321K sold.

Ergoteles first reported a position in AUTL in Q4 2022 and held it in 1 quarter. The position peaked at $321K in Q4 2022. 65 funds tracked by Wall St. Rank hold AUTL as of Q1 2023.

  • Ergoteles reported no remaining Autolus Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 169,180 Autolus Therapeutics shares in Q1 2023, an estimated $321K.
  • Ergoteles first reported a position in Autolus Therapeutics in Q4 2022 and held it in 1 quarter.
  • Ergoteles's Autolus Therapeutics position peaked at $321K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.